

Philippe Gatault

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7977684/publications.pdf>

Version: 2024-02-01

33
papers

1,253
citations

516215

16
h-index

414034

32
g-index

35
all docs

35
docs citations

35
times ranked

1988
citing authors

#	ARTICLE	IF	CITATIONS
1	Early Administration of Anti-SARS-CoV-2 Monoclonal Antibodies Prevents Severe COVID-19 in Kidney Transplant Patients. <i>Kidney International Reports</i> , 2022, 7, 1241-1247.	0.4	25
2	Is COVID-19 infection more severe in kidney transplant recipients?. <i>American Journal of Transplantation</i> , 2021, 21, 1295-1303.	2.6	190
3	Response to plasma exchange and graft survival in recurrent focal and segmental glomerulosclerosis after transplantation: does the time of recurrence matter? A retrospective study. <i>Transplant International</i> , 2021, 34, 302-312.	0.8	0
4	Feasibility and safety of tailored dosing schedule for eculizumab based on therapeutic drug monitoring: Lessons from a prospective multicentric study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2236-2246.	1.1	10
5	Rat and human cytomegalovirus ORF116 encodes a virion envelope glycoprotein required for infectivity. <i>Virology</i> , 2021, 557, 23-33.	1.1	6
6	Relationship Between Antithymocyte Globulin Concentrations and Lymphocyte Sub-Populations in Kidney Transplant Patients. <i>Clinical Pharmacokinetics</i> , 2021, , 1.	1.6	0
7	Major Bleeding of Transjugular Native Kidney Biopsies. A French Nationwide Cohort Study. <i>Kidney International Reports</i> , 2021, 6, 2594-2603.	0.4	9
8	Clinical Utility of Biochemical Markers for the Prediction of COVID-19-Related Mortality in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2021, 6, 2689-2693.	0.4	8
9	Occurrence of severe COVID-19 in vaccinated transplant patients. <i>Kidney International</i> , 2021, 100, 477-479.	2.6	101
10	Successful treatment of acute kidney allograft rejection using extracorporeal photopheresis in the context of post-transplant lymphoproliferative diseases: three successive cases. <i>Transplant International</i> , 2021, 34, 2415-2417.	0.8	2
11	Antibody Responses after a Third Dose of COVID-19 Vaccine in Kidney Transplant Recipients and Patients Treated for Chronic Lymphocytic Leukemia. <i>Vaccines</i> , 2021, 9, 1055.	2.1	40
12	Major Bleeding and Risk of Death after Percutaneous Native Kidney Biopsies. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020, 15, 1587-1594.	2.2	49
13	An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. <i>Kidney International</i> , 2020, 98, 1549-1558.	2.6	213
14	Opportunistic Infections and Efficacy Following Conversion to Belatacept-Based Therapy after Kidney Transplantation: A French Multicenter Cohort. <i>Journal of Clinical Medicine</i> , 2020, 9, 3479.	1.0	17
15	IMPact of the COVID-19 epidemic on the moRTality of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT). <i>Kidney International</i> , 2020, 98, 1568-1577.	2.6	85
16	Opportunistic infections after conversion to belatacept in kidney transplantation. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 336-345.	0.4	54
17	An extension of the RITUXERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody-mediated rejection after renal transplantation. <i>Transplant International</i> , 2020, 33, 786-795.	0.8	18
18	The Fc γ RIIIA Δ 158 VV genotype increased the risk of post-transplant lymphoproliferative disorder in T α cell-depleted kidney transplant recipients - a retrospective study. <i>Transplant International</i> , 2020, 33, 936-947.	0.8	3

#	ARTICLE	IF	CITATIONS
19	Early Acute Microvascular Kidney Transplant Rejection in the Absence of Anti-HLA Antibodies Is Associated with Preformed IgG Antibodies against Diverse Glomerular Endothelial Cell Antigens. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 692-709.	3.0	81
20	Transplant center characteristics associated with living donor kidney transplantation: a cohort study with a hierarchical modeling approach. <i>Transplant International</i> , 2019, 32, 865-875.	0.8	1
21	CMV disease and colitis in a kidney transplanted patient under pembrolizumab. <i>European Journal of Cancer</i> , 2019, 109, 172-174.	1.3	13
22	Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2449-2463.	3.0	81
23	CMV-infected kidney grafts drive the expansion of blood-borne CMV-specific T cells restricted by shared class I HLA molecules via presentation on donor cells. <i>American Journal of Transplantation</i> , 2018, 18, 1904-1913.	2.6	9
24	Predictive factors of spontaneous CMV DNAemia clearance in kidney transplantation. <i>Journal of Clinical Virology</i> , 2018, 99-100, 38-43.	1.6	4
25	Prognostic Value of the Persistence of C1q-Binding Anti-HLA Antibodies in Acute Antibody-Mediated Rejection in Kidney Transplantation. <i>Transplantation</i> , 2018, 102, 688-698.	0.5	31
26	Progression of Mineral Ion Abnormalities in Patients With Jansen Metaphyseal Chondrodysplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 2660-2669.	1.8	17
27	The age-calibrated measured glomerular filtration rate improves living kidney donation selection process. <i>Kidney International</i> , 2018, 94, 616-624.	2.6	28
28	Development and validation of an enzyme-linked immunosorbent assay to measure free eculizumab concentration in serum. <i>Bioanalysis</i> , 2017, 9, 1227-1235.	0.6	9
29	Polymorphism in programmed cell death 1 gene is strongly associated with lung and kidney allograft survival in recipients from CMV-positive donors. <i>Journal of Heart and Lung Transplantation</i> , 2017, 36, 315-324.	0.3	10
30	Eight-year results of the Spiesser study, a randomized trial comparing <i>de novo</i> sirolimus and cyclosporine in renal transplantation. <i>Transplant International</i> , 2016, 29, 41-50.	0.8	32
31	Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule. <i>MAbs</i> , 2015, 7, 1205-1211.	2.6	67
32	Community pharmacist intervention in patients with renal impairment. <i>International Journal of Clinical Pharmacy</i> , 2015, 37, 1172-1179.	1.0	18
33	Conversion to mTOR-inhibitor-based immunosuppression: which patients and when?. <i>Transplantation Research</i> , 2013, 2, S3.	1.5	20